Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13171509 | 0.81 | PDE10A (0.42) | BTKTRPV3GABRA1GABRB2 | |
| SCHEMBL13171557 | 0.81 | HTR1B (0.37) | BTKTRPV3 | |
| SCHEMBL12641680 | 0.81 | MAPK8 (0.49) | MAPK8BTKTRPV3NPC1ALDH1A1 | |
| SCHEMBL13171564 | 0.80 | HTR1B (0.38) | BTKTRPV3 | |
| SCHEMBL3625374 | 0.78 | GABRA1 (0.44) | GABRA1GABRB2ADORA1 | |
| SCHEMBL2525163 | 0.78 | MAPK8 (0.56) | MAPK8BTKNPC1ALDH1A1MAPK1 | |
| SCHEMBL1536741 | 0.78 | MAPK8 (0.50) | MAPK8BTKTRPV3NPC1ALDH1A1 | |
| SCHEMBL126589 | 0.78 | MAPK8 (0.46) | MAPK8BTKTRPV3NPC1ALDH1A1 | |
| SCHEMBL18266390 | 0.78 | MAPK8 (0.46) | MAPK8BTKTRPV3NPC1ALDH1A1 | |
| SCHEMBL12641679 | 0.78 | CYP1A2 (0.43) | BTKTRPV3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012082689-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | MAPK8 586/4885BTK 38/4885TRPV3 168/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | MAPK8 725/4885BTK 33/4885TRPV3 318/4885 |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | MAPK8 1486/4885BTK 193/4885TRPV3 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.